Dramatic response to intravitreal Bevacizumab in hypertensive retinopathy

Hypertensive retinopathy is seen frequently in patients with systemic hypertension and is usually asymptomatic. An acute rise in blood pressure may lead to exudative changes in the form of macular edema, hemorrhages, and serous macular detachment that can lead to visual decline. The authors report prompt resolution of exudative changes in a case of hypertensive retinopathy following intravitreal bevacizumab.

[1]  A. Al-Halafi.  Tremendous result of bevacizumab in malignant hypertensive retinopathy , 2015, Oman journal of ophthalmology.

[2]  I. Chowers,et al.  Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema , 2014, Eye.

[3]  Ji Hun Song,et al.  Effect of intravitreal bevacizumab (Avastin(®)) therapy in malignant hypertensive retinopathy: a report of two cases. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[4]  A. Schachat,et al.  A review of clinical trials of anti-VEGF agents for diabetic retinopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[5]  H. Hense,et al.  Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. , 2003, JAMA.

[6]  M. Tso,et al.  Pathophysiology of hypertensive retinopathy. , 1982, Ophthalmology.

[7]  Abdelrahman Salman.  Intravitreal bevacizumab in persistent retinopathy secondary to malignant hypertension. , 2013, Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society.

[8]  J. Singh,et al.  Hypertensive retinopathy. , 1983, Indian journal of ophthalmology.